Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
November 08, 2022 13:05 ET
|
Curium
Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain resilienceCooperation, investment, and facility upgrades for the benefit of patients ...
Global Prostate Cancer Nuclear Medicine Diagnostics Market Report 2022-2028 - Increasing Research Activities for Development of Innovative Imaging Agents
August 31, 2022 06:28 ET
|
Research and Markets
Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report...
Radiopharmaceuticals Global Market Report 2022: Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
August 23, 2022 06:13 ET
|
Research and Markets
Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
June 27, 2022 01:00 ET
|
Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
May 12, 2022 01:05 ET
|
Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
May 03, 2022 01:05 ET
|
Curium
ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized...
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
April 19, 2022 01:00 ET
|
Curium
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
April 05, 2022 01:05 ET
|
Curium
ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...
Monopar Announces Clinical and Preclinical Program Updates
February 15, 2022 08:05 ET
|
Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...
Global Radiopharmaceuticals Market Analysis Report 2021: Market to Reach $8.9 Billion by 2026 - COVID-19 Presents Generational Opportunity
January 27, 2022 04:43 ET
|
Research and Markets
Dublin, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...